Portage Biotech Inc. (NASDAQ:PRTG) Short Interest Up 15.2% in January

Portage Biotech Inc. (NASDAQ:PRTG) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 22,800 shares, an increase of 15.2% from the January 15th total of 19,800 shares. Based on an average daily trading volume, of 653,800 shares, the short-interest ratio is presently 0.0 days. Approximately 5.2% of the shares of the stock are short sold.

Institutional Investors Weigh In On Portage Biotech

An institutional investor recently bought a new position in Portage Biotech stock. Virtu Financial LLC purchased a new stake in shares of Portage Biotech Inc. (NASDAQ:PRTG) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned approximately 1.04% of Portage Biotech at the end of the most recent reporting period. 13.36% of the stock is owned by institutional investors and hedge funds.

Portage Biotech Price Performance

Shares of PRTG traded down $0.23 during mid-day trading on Friday, reaching $4.61. The company had a trading volume of 7,785 shares, compared to its average volume of 129,256. Portage Biotech has a twelve month low of $2.10 and a twelve month high of $23.01. The company’s 50-day moving average is $4.74 and its 200-day moving average is $4.82. The company has a market capitalization of $4.84 million, a P/E ratio of -0.11 and a beta of 1.31.

Portage Biotech (NASDAQ:PRTG) last issued its earnings results on Tuesday, November 26th. The company reported ($1.26) earnings per share (EPS) for the quarter.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.